DNA

Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients

Extensive Scientific Evidence Supporting Growth Factor Receptor Bound Protein-2 (Grb2) as Fundamental Link in Insulin Resistance Reallocates Resources to Metabolic…

1 year ago

EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant…

1 year ago

Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed…

1 year ago

healthŌme and Hannover Re Win 2024 Global Innovation Award for Genomics-Based Insurance Program

Award honors the integration of genomics into critical illness coverage, enhancing the value of life and critical illness products for…

1 year ago

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Press Release – No. 12 / 2024 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide…

1 year ago

H1 Partners with CTI to Streamline Clinical Trial PI and Site Selection for More Inclusive and Efficient Trials

Leading Contract Research Organization integrates H1’s Trial Landscape platform to optimize global site selection, enhance diversity efforts, and streamline operational…

1 year ago

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001

Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT)…

1 year ago

Teams Announced for the 2024 StaffDNA® Cure Bowl

PLANO, Texas, Dec. 9, 2024 /PRNewswire/ -- ESPN Events along with the Orlando Sports Foundation (OSF) announced that Jacksonville State…

1 year ago

Senseonics Holdings, Inc. Provides Update on Eversense 365 Launch

Strong Eversense® 365 early launch indicators illustrated by largest number of new patient shipments and largest number of prescribing providers…

1 year ago

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies…

1 year ago